Status:
COMPLETED
A Comparison of Sertraline Versus Venlafaxine XR in the Treatment of Major Depression
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Depressive Disorder, Major
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To assess the comparative efficacy of sertraline versus venlafaxine XR on measures of quality of life.
Eligibility Criteria
Inclusion
- Primary diagnosis of DSM-IV Major Depressive Disorder, single episode or recurrent, without psychotic features. Additional DSM-IV Axis I diagnoses will be permitted only if they are identified as secondary diagnoses.
- Hamilton-Depression rating scale (HAM-D; 17 item) total score ≥18 and HAMD item 1 (depressed mood) score ≥2.
Exclusion
- Use of an antidepressant within 2 weeks of baseline (4 weeks for fluoxetine)
- Current or past diagnosis of bipolar disorder or any psychotic disorder.
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2003
Estimated Enrollment :
163 Patients enrolled
Trial Details
Trial ID
NCT00644982
Start Date
October 1 2002
End Date
September 1 2003
Last Update
January 27 2021
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Cairns, Queensland, Australia, 4870
2
Pfizer Investigational Site
Everton Park, Queensland, Australia, 4053
3
Pfizer Investigational Site
North Cairns, Queensland, Australia, 4870
4
Pfizer Investigational Site
Box Hill, Victoria, Australia, 3128